High-dose antifungal for widespread Histoplasmosis in HIV
Part of Immune system & allergy, Infections clinical trials.
This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult and being treated at one of the study hospitals
- You have HIV (antiretroviral treatment use can be ongoing or not)
- You have confirmed widespread (disseminated) Histoplasmosis by lab testing (like cultures, microscopy, tissue testing, or urine antigen test)
- If you have a brain/spinal infection, doctors think there’s an alternative explanation, not Histoplasmosis in the CNS
- You’re not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations and timing of antifungal medicines to treat histoplasmosis, a lung infection, in hospitalized patients. It aims to find the safest and most effective way to cure the infection.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.